

Anne W M Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8604032/publications.pdf>

Version: 2024-02-01

123
papers

8,969
citations

61857

43
h-index

43802

91
g-index

127
all docs

127
docs citations

127
times ranked

7342
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 59-68.	0.9	18
2	In Reply to Abbasi et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 262-263.	0.4	0
3	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. <i>Radiotherapy and Oncology</i> , 2022, 167, 179-186.	0.3	8
4	Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management – A Systematic Review. <i>Cancer Management and Research</i> , 2022, Volume 14, 339-366.	0.9	9
5	Management of Nasopharyngeal Carcinoma in Elderly Patients. <i>Frontiers in Oncology</i> , 2022, 12, 810690.	1.3	5
6	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma – Magic Bullet or Pandora’s Box?. <i>JAMA Oncology</i> , 2022, , .	3.4	2
7	The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours. <i>Advances in Therapy</i> , 2022, 39, 2379-2397.	1.3	6
8	Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2679-2689.	3.2	4
9	Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1135-1138.	0.8	1
10	Near-Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti-EPD Immunotherapy against Metastatic Tumors. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101496.	3.9	12
11	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. <i>Cancers</i> , 2022, 14, 1923.	1.7	1
12	Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 2122.	1.7	7
13	A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin. <i>Frontiers in Oncology</i> , 2022, 12, 842281.	1.3	1
14	Diagnosis and Staging of Nasopharyngeal Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 1-21.	0.0	0
15	Incidence and Demographics of Nasopharyngeal Carcinoma in Cheung Chau Island of Hong Kong – A Distinct Geographical Area With Minimal Residential Mobility and Restricted Public Healthcare Referral Network. <i>Cancer Control</i> , 2021, 28, 107327482110471.	0.7	2
16	The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 626145.	1.3	9
17	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	0.8	178
18	Contemporary management of the neck in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2021, 43, 1949-1963.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies. <i>Oral Oncology</i> , 2021, 114, 105158.	0.8	7
20	Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. <i>Nature Communications</i> , 2021, 12, 1540.	5.8	88
21	Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021, 43, 2807-2821.	0.9	4
22	Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6046-6046.	0.8	0
23	A potential survival impact of blood immune cells in patients with locoregionally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18027-e18027.	0.8	0
24	Cisplatin and capecitabine induction chemotherapy in nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6065-6065.	0.8	2
25	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e217.	5.1	0
26	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.4	42
27	External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma. <i>Cancers</i> , 2021, 13, 4286.	1.7	4
28	A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2021, 153, 109-122.	1.3	48
29	Low vitamin D exposure and risk of nasopharyngeal carcinoma: Observational and genetic evidence from a multicenter caseâ€“control study. <i>Clinical Nutrition</i> , 2021, 40, 5180-5188.	2.3	1
30	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 744889.	1.3	19
31	Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor. <i>Cancer Letters</i> , 2021, 522, 238-254.	3.2	14
32	Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 1148.	1.3	5
33	Comparing dyadic cognitive behavioral therapy (CBT) with dyadic integrative body-mind-spirit intervention (I-BMS) for Chinese family caregivers of lung cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2020, 28, 1523-1533.	1.0	23
34	Dose volume effects of reâ€“irradiation for locally recurrent nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 180-187.	0.9	11
35	Quality of end-of-life care of advanced cancer patients in mainland Chinaâ€“a retrospective cohort of 441 hospital-death in a public funded comprehensive hospital. <i>Annals of Palliative Medicine</i> , 2020, 9, 4514-4520.	0.5	2
36	Emerging radiotherapy technologies and trends in nasopharyngeal cancer. <i>Cancer Communications</i> , 2020, 40, 395-405.	3.7	18

#	ARTICLE	IF	CITATIONS
37	Role of miR-96/EVI1/miR-449a Axis in the Nasopharyngeal Carcinoma Cell Migration and Tumor Sphere Formation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5495.	1.8	8
38	Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1417.	1.3	11
39	Radiotherapy in the management of glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3558-3567.	0.9	9
40	Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. <i>Communications Biology</i> , 2020, 3, 759.	2.0	17
41	Advocacy to provide good quality oncology services during the COVID-19 pandemic – Actions at 3-levels. <i>Radiotherapy and Oncology</i> , 2020, 149, 25-29.	0.3	10
42	NPC – 0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2020, 126, 3674-3688.	2.0	37
43	Current management of stage IV nasopharyngeal carcinoma without distant metastasis. <i>Cancer Treatment Reviews</i> , 2020, 85, 101995.	3.4	28
44	COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. <i>Head and Neck</i> , 2020, 42, 1259-1267.	0.9	218
45	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6523-6523.	0.8	14
46	Excessive mortality in 1,353 five-year survivors of nasopharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24090-e24090.	0.8	0
47	Phase II study of consolidative intensity-modulated radiation therapy following first-line palliative systemic chemotherapy for de novo previously untreated metastatic (M1) nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6524-6524.	0.8	2
48	Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures. <i>BMC Public Health</i> , 2019, 19, 1065.	1.2	10
49	Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT – A study by the HKNPCSC. <i>Head and Neck</i> , 2019, 41, 3661-3669.	0.9	28
50	Management of locally recurrent nasopharyngeal carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 79, 101890.	3.4	186
51	Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. <i>British Journal of Cancer</i> , 2019, 121, 690-698.	2.9	19
52	Standard of Care for Nasopharyngeal Carcinoma (2018 – 2020). , 2019, , 205-238.		1
53	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	3.0	56
54	Staging of Nasopharyngeal Carcinoma Based on the 8th Edition of the AJCC/UICC Staging System. , 2019, , 179-203.		2

#	ARTICLE	IF	CITATIONS
55	Radiotherapy toxicity. <i>Nature Reviews Disease Primers</i> , 2019, 5, 13.	18.1	434
56	The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. <i>International Journal of Cancer</i> , 2019, 144, 1713-1722.	2.3	82
57	Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lung cancer and their family caregivers. <i>Journal of Evidence-informed Social Work</i> , 2018, 15, 258-276.	0.8	9
58	Radiation-induced carotid artery lesions. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 699-710.	1.0	46
59	Head and neck cancer in Hong Kong. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 13-21.	0.6	10
60	Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 630-638.	0.4	34
61	Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma—Exploration for Achieving Optimal 10-Year Therapeutic Ratio. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1078-1086.	0.4	23
62	Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). <i>Oral Oncology</i> , 2018, 77, 16-21.	0.8	189
63	The Wnt modulator ICG001 mediates the inhibition of nasopharyngeal carcinoma cell migration in vitro via the miR-150/CD44 axis. <i>International Journal of Oncology</i> , 2018, 54, 1010-1020.	1.4	12
64	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , 2018, 4, 1073.	3.4	44
65	Editorial: Data Based Radiation Oncology—Design of Clinical Trials. <i>Frontiers in Oncology</i> , 2018, 8, 34.	1.3	0
66	Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in Hong Kong Chinese. <i>International Journal of Cancer</i> , 2018, 143, 2289-2298.	2.3	9
67	Prognostic role of pretreatment plasma EBV DNA on stage III nasopharyngeal carcinoma staged by AJCC/UICC 8 th edition TNM staging classification. <i>Journal of Clinical Oncology</i> , 2018, 36, 6055-6055.	0.8	0
68	Reply to Nomograms need to be presented in full. <i>Cancer</i> , 2017, 123, 178-179.	2.0	0
69	Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 533-540.	0.9	57
70	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	37
71	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 498-505.	0.8	263
72	The impact of palliative care training for oncologists and integrative palliative service in a public-funded hospital cluster—a retrospective cohort study. <i>Supportive Care in Cancer</i> , 2017, 26, 1393-1399.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Metronomic oral cyclophosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma. <i>Medicine (United States)</i> , 2017, 96, e6518.	0.4	5
74	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , 2017, 123, 4147-4157.	2.0	70
75	Title is missing!. , 2017, , .		6
76	Proposal for the 8th edition of the <sc>AJCC</sc>/<sc>UICC</sc> staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , 2016, 122, 546-558.	2.0	254
77	Whole-exome sequencing identifies multiple loss-of-function mutations of NF- κ B pathway regulators in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11283-11288.	3.3	144
78	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , 2016, 122, 3307-3315.	2.0	125
79	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , 2016, 38, E2151-8.	0.9	146
80	Whole-exome sequencing identifies <i>MST1R</i> as a genetic susceptibility gene in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3317-3322.	3.3	71
81	The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. <i>Chinese Clinical Oncology</i> , 2016, 5, 27-27.	0.4	4
82	Factors correlating with shorter survival after treatment: Aiding oncologists to choose who (not) to receive palliative systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21654-e21654.	0.8	0
83	Chemotherapy for Nasopharyngeal Carcinoma â€œ Current Recommendation and Controversies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1107-1122.	0.9	39
84	Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. <i>Current Treatment Options in Oncology</i> , 2015, 16, 44.	1.3	16
85	Preliminary results of trial NPCâ€œ0501 evaluating the therapeutic gain by changing from concurrentâ€œadjuvant to inductionâ€œconcurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 1328-1338.	2.0	152
86	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , 2015, 33, 3356-3364.	0.8	579
87	Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylationâ€œsensitive high resolution melting. <i>International Journal of Cancer</i> , 2015, 136, E127-35.	2.3	72
88	The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. <i>Oral Oncology</i> , 2014, 50, 506-512.	0.8	83
89	Evolution of treatment for nasopharyngeal cancer â€œ Success and setback in the intensity-modulated radiotherapy era. <i>Radiotherapy and Oncology</i> , 2014, 110, 377-384.	0.3	300
90	Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4?. <i>Oral Oncology</i> , 2014, 50, 1188-1195.	0.8	30

#	ARTICLE	IF	CITATIONS
91	Staging of nasopharyngeal carcinoma – The past, the present and the future. <i>Oral Oncology</i> , 2014, 50, 549-554.	0.8	47
92	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 6022-6022.	0.8	5
93	Secular trends of salted fish consumption and nasopharyngeal carcinoma: a multi-jurisdiction ecological study in 8 regions from 3 continents. <i>BMC Cancer</i> , 2013, 13, 298.	1.1	30
94	The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. <i>Oral Oncology</i> , 2012, 48, 1007-1013.	0.8	109
95	Role of STAT3/5 and Bcl-2/xL in 2- <i>methoxyestradiol</i> -induced endoreduplication of nasopharyngeal carcinoma cells. <i>Molecular Carcinogenesis</i> , 2012, 51, 963-972.	1.3	10
96	If concurrent – adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction – concurrent achieve better outcome?. <i>Journal of Radiation Oncology</i> , 2012, 1, 107-115.	0.7	18
97	Current Management of Nasopharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , 2012, 22, 233-244.	1.0	274
98	Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: The importance of co-morbidity assessment. <i>Oral Oncology</i> , 2012, 48, 162-167.	0.8	38
99	Factors contributing to the efficacy of concurrent – adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials. <i>European Journal of Cancer</i> , 2011, 47, 656-666.	1.3	196
100	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2011, 98, 15-22.	0.3	102
101	Clinical Outcomes and Patterns of Failure After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 420-428.	0.4	236
102	Impact of adjuvant chemoradiation for adenocarcinoma of stomach after curative gastrectomy in Chinese: A 7- <i>year</i> audit. <i>Surgical Practice</i> , 2010, 14, 85-91.	0.1	0
103	Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1188-1198.	3.0	298
104	Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients – the Hong Kong experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 123-128.	0.7	4
105	Sensorineural Hearing Loss After Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1335-1342.	0.4	98
106	Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2008, 87, 204-210.	0.3	90
107	N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: Pattern of nodal involvement by radiological levels. <i>Radiotherapy and Oncology</i> , 2007, 82, 70-75.	0.3	84
108	Current Management Strategies for Non-Metastatic Nasopharyngeal Cancer. <i>American Journal of Cancer</i> , 2006, 5, 383-392.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: A study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). <i>Radiotherapy and Oncology</i> , 2006, 79, 27-33.	0.3	66
110	Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 142-151.	0.4	151
111	Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1107-1116.	0.4	536
112	Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1331-1338.	0.4	66
113	Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. <i>Head and Neck</i> , 2005, 27, 397-405.	0.9	157
114	Screening for family members of patients with nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2005, 113, 998-1001.	2.3	67
115	Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 6966-6975.	0.8	420
116	Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 21-27.	0.4	710
117	Contribution of Radiotherapy to Function Preservation and Cancer Outcome in Primary Treatment of Nasopharyngeal Carcinoma. <i>World Journal of Surgery</i> , 2003, 27, 838-843.	0.8	15
118	Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): An encouraging reduction in both incidence and mortality. <i>International Journal of Cancer</i> , 2003, 103, 680-685.	2.3	166
119	Measuring quality of life of Chinese cancer patients. <i>Cancer</i> , 2000, 88, 1715-1727.	2.0	120
120	Total biological effect on late reactive tissues following reirradiation for recurrent nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 865-872.	0.4	51
121	Measuring quality of life of Chinese cancer patients. , 2000, 88, 1715.		7
122	Staging of nasopharyngeal carcinoma: From Ho's to the new UICC system. , 1999, 84, 179-187.		80
123	Reirradiation for recurrent nasopharyngeal carcinoma: Factors affecting the therapeutic ratio and ways for improvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 43-52.	0.4	144